UK drug update - January 2004

Published: 1-Jan-2004
Regulatory


PLIVA Pharma has launched 50mg and 100mg tablets of the antibiotic minocycline.

Celltech has expanded its Minijet range with the addition of 1mg/mL of the opiate morphine sulphate in prefilled syringes.

Merck Pharmaceuticals has introduced Niaspan modified-release tablets. The tablets contain 375mg, 500mg, 750mg or 1g of the lipid-regulating drug nicotinic acid.

Gilead Sciences has marketed Emtriva capsules containing 200mg of the nucleoside reverse transcriptase inhibitor emtricitabine.

APS/Berk has introduced 100mg, 200mg, 300mg, 600mg and 800mg capsules of the anticonvulsant gabapentin. The company has also marketed Keloc SR tablets containing 5mg or 10mg of the class II calcium antagonist felodipine.

Provalis has launched Salofalk granules, containing 500mg or 1g of the aminosalicylate mesalazine.

Orion Pharma has launched Stalevo tablets containing the dopamine precursor/dopa decarboxylase inhibitor and COMT inhibitor levodopa/carbidopa/entacapone in the following combinations: 50mg/12.5mg/200mg, 100mg/25mg/200mg and 150mg/37.5mg/200mg, respectively.

Baxter Healthcare has marketed a subcutaneous human normal immunoglobulin called Subcuvia, available as 5mL or 10mL vials.

Auden Mckenzie has brought out Synastone. The product comprises 50mg/1mL or 50mg/2mL ampoules of the opiate methadone.

Almus has made available 80mg tablets of the sulphonylurea gliclazide.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now